...
首页> 外文期刊>Clinical and applied thrombosis/hemostasis : >The Utilization of Antithrombotic Therapy in Older Patients in Aged Care Facilities With Atrial Fibrillation
【24h】

The Utilization of Antithrombotic Therapy in Older Patients in Aged Care Facilities With Atrial Fibrillation

机译:心房颤动老年护理设施中老年患者的抗栓治疗

获取原文
           

摘要

Oral anticoagulants are essential drugs for the prevention of thromboembolic events in patients with atrial fibrillation (AF). Anticoagulants are, however, commonly withheld in older people due to the risk and fear of hemorrhage. Although the underutilization of anticoagulants in patients with AF has been demonstrated internationally, few studies have been conducted among aged care residents. The aim of this study was to determine the utilization of anticoagulants among people with AF residing in aged care facilities. We performed a non-experimental, retrospective analysis designed to evaluate antithrombotic usage in patients with AF in Australia residing in aged care facilities, using data collected by pharmacists while performing Residential Medication Management Reviews (RMMRs). The utilization of antithrombotic therapy and the appropriateness of therapy were determined based on the CHADS2, CHA2DS2-VASc, and HAS-BLED risk stratification schemes in consideration of documented contraindications to treatment. Predictors of anticoagulant use were determined using multivariate logistic regression. A total of 1952 RMMR patients with AF were identified. Only 35.6% of eligible patients (CHADS2 score ≥2 and no contraindications to anticoagulants) received an anticoagulant. As age increased, the likelihood of receiving an anticoagulant decreased and the likelihood of receiving an antiplatelet or no therapy increased. In patients at high risk of stroke (CHADS score ≥2), utilization of anticoagulants dropped by 19.7% when the HAS-BLED score increased from 2 to 3, suggesting that physicians placed a heavier weighting on bleeding risk rather than stroke risk. Prescribing of anticoagulants was influenced to a greater extent by bleeding risk than it was by the risk of stroke. Further research investigating whether the growing availability of direct oral anticoagulants influences practice in this patient population is needed.
机译:口服抗凝剂是预防房颤(AF)患者血栓栓塞事件的基本药物。然而,由于存在出血的风险和恐惧,抗凝剂在老年人中通常不被使用。尽管国际上已证明房颤患者抗凝药的利用不足,但在老年护理居民中进行的研究很少。这项研究的目的是确定居住在老年护理机构中的房颤患者中抗凝剂的利用情况。我们进行了一项非实验性回顾性分析,旨在评估药剂师在执行《居住药物管理评论》(RMMR)时居住在老年护理设施中的澳大利亚房颤患者的抗血栓形成情况。考虑到已记录的治疗禁忌症,根据CHADS2,CHA2DS2-VASc和HAS-BLED风险分层方案确定了抗血栓治疗的利用和治疗的适当性。使用多因素logistic回归确定抗凝药使用的预测指标。总共确定了1952名RMMR房颤患者。只有35.6%的合格患者(CHADS2评分≥2,且无抗凝药禁忌症)接受抗凝药。随着年龄的增长,接受抗凝剂的可能性降低,接受抗血小板或不接受治疗的可能性增加。在具有高中风风险(CHADS评分≥2)的患者中,当HAS-BLED评分从2增至3时,抗凝剂的使用率下降了19.7%,这表明医生对出血风险而非中风风险的重视程度更高。与出血风险相比,出血风险对抗凝剂处方的影响更大。需要进一步研究直接口服抗凝药的日益增长是否会影响该患者人群的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号